Literature DB >> 26396925

Clinical significance and prognostic value of Vav1 expression in Non-small cell lung cancer.

Yao Qi1, Fan-Ming Kong2, Qi Deng1, Jing-Yi Li1, Rui Cui1, Ye-Di Pu1, Qiong-Li Zhai3, Ying-Jie Jia2, Yu-Ming Li1.   

Abstract

Vav1 has been reported to be involved in human cancers, however, the expression and clinical significance of Vav1 in NSCLC are not fully understood. In the present study, we examined the expression of Vav1 in 170 NSCLC patients who underwent radical resection by the immunohistochemical analyses. The association between the Vav1 expression and clinicopathological variables was analyzed. The multivariate Cox proportional hazards model was conducted to determine the prognostic value of Vav1 on the long-term survival. The results showed that the elevated Vav1 expression was correlated positively with lymph node metastasis (P<0.001), T stage (P<0.001) and poor histological differentiation (P<0.001). Patients with negative or low Vav1 expression had better prognoses than those with high Vav1 expression (P<0.001). Multivariate analysis indicated that Vav1 was independent prognostic factor for overall survival (OS) (HR 2.079, 95% CI 1.564 to 2.762, P<0.001) and disease-free survival (DFS) (HR 1.810, 95% CI 1.391 to 2.356, P<0.001). Our findings showed that overexpressed Vav1 was correlated with aggressive tumor behavior. Val1 was an independent factor for NSCLC prognosis, which may serve as a novel prognostic factor and potential target to improve the long-term outcome of NSCLC.

Entities:  

Keywords:  Vav1; invasion; non-small cell lung cancer; prognosis

Year:  2015        PMID: 26396925      PMCID: PMC4568785     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  26 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 2.  Vav1 in differentiation of tumoral promyelocytes.

Authors:  Valeria Bertagnolo; Federica Brugnoli; Silvia Grassilli; Ervin Nika; Silvano Capitani
Journal:  Cell Signal       Date:  2011-11-28       Impact factor: 4.315

Review 3.  [What's new in the 2004 WHO classification of the lung tumors?].

Authors:  S Lantuéjoul; E Brambilla
Journal:  Rev Pneumol Clin       Date:  2008-09-17

4.  Costimulation: building an immunological synapse.

Authors:  M L Dustin; A S Shaw
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

5.  Lck regulates Vav activation of members of the Rho family of GTPases.

Authors:  J Han; B Das; W Wei; L Van Aelst; R D Mosteller; R Khosravi-Far; J K Westwick; C J Der; D Broek
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

6.  Mechanism of activation of the vav protooncogene.

Authors:  J Coppola; S Bryant; T Koda; D Conway; M Barbacid
Journal:  Cell Growth Differ       Date:  1991-02

Review 7.  Vav-family proteins in T-cell signalling.

Authors:  Victor L J Tybulewicz
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

8.  VAV1 represses E-cadherin expression through the transactivation of Snail and Slug: a potential mechanism for aberrant epithelial to mesenchymal transition in human epithelial ovarian cancer.

Authors:  Senn Wakahashi; Tamotsu Sudo; Noriko Oka; Sayaka Ueno; Satoshi Yamaguchi; Kiyoshi Fujiwara; Chiho Ohbayashi; Ryuichiro Nishimura
Journal:  Transl Res       Date:  2013-07-12       Impact factor: 7.012

9.  Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product.

Authors:  P Crespo; K E Schuebel; A A Ostrom; J S Gutkind; X R Bustelo
Journal:  Nature       Date:  1997-01-09       Impact factor: 49.962

10.  The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas.

Authors:  Idit Hornstein; Eli Pikarsky; Maya Groysman; Gail Amir; Nili Peylan-Ramu; Shulamit Katzav
Journal:  J Pathol       Date:  2003-04       Impact factor: 7.996

View more
  5 in total

1.  TGFβ promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1.

Authors:  P-H Huang; P-J Lu; L-Y Ding; P-C Chu; W-Y Hsu; C-S Chen; C-C Tsao; B-H Chen; C-T Lee; Y-S Shan; C-S Chen
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

2.  Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.

Authors:  Sofia Khazan-Kost; Gal Cafri; Dganit Melamed Kadosh; Navit Mooshayef; Sumit Chatterji; Dan Dominissini; Sigal Manor; Bracha Zisser; Limor Broday; Efrosiniia Talalai; Anat Shemer; Oranit Zadok; Efrat Ofek; Amir Onn; Arie Admon; Michael Peled
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

3.  Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome.

Authors:  Silvia Grassilli; Federica Brugnoli; Rossano Lattanzio; Marco Marchisio; Letizia Perracchio; Mauro Piantelli; Alberto Bavelloni; Silvano Capitani; Valeria Bertagnolo
Journal:  Mol Oncol       Date:  2018-05-16       Impact factor: 6.603

4.  Vav1 Sustains the In Vitro Differentiation of Normal and Tumor Precursors to Insulin Producing Cells Induced by all-Trans Retinoic Acid (ATRA).

Authors:  Federica Brugnoli; Silvia Grassilli; Vincenzo Cardinale; Guido Carpino; Eugenio Gaudio; Domenico Alvaro; Silvano Capitani; Valeria Bertagnolo
Journal:  Stem Cell Rev Rep       Date:  2020-11-09       Impact factor: 5.739

5.  Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Authors:  Federico Rotolo; Chang-Qi Zhu; Elisabeth Brambilla; Stephen L Graziano; Ken Olaussen; Thierry Le-Chevalier; Jean-Pierre Pignon; Robert Kratzke; Jean-Charles Soria; Frances A Shepherd; Lesley Seymour; Stefan Michiels; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2018-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.